Long‐term treatment of patients with gastro‐oesophageal reflux disease in routine care – results from the ProGERD study
- 22 January 2007
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (6) , 715-722
- https://doi.org/10.1111/j.1365-2036.2007.03249.x
Abstract
Gastro-oesophageal reflux disease (GERD) is a common condition frequently requiring long-term pharmacological treatment. To describe the long-term pattern of GERD medication use in GERD patients receiving routine care. Patients were recruited as part of the ongoing ProGERD study, a 10-year-cohort study including 6215 patients at baseline. GERD medication and symptoms were assessed with patient questionnaires. During follow-up, medical treatment was prescribed by participating primary care physicians. Associations between patient characteristics and medication were analysed by logistic regression. The percentage of patients who reported using any GERD medication remained constant from year 1 to year 4 (74%, 74%, 73% and 71%). Of patients who reported using GERD medication, the majority were taking proton pump inhibitors (PPI) (79%, 84%, 85%, and 87%). Continuous PPI intake was the predominant prescription pattern (53%, 49%, 56% and 56%), followed by on-demand treatment (26%, 35%, 29% and 29%). Continuous PPI intake was strongly associated with the presence of erosive GERD. Three-quarters of the GERD population in our study reported long-term treatment with a PPI. Continuous PPI intake was the predominant treatment pattern, and the proportion of patients taking a PPI on a continuous basis remained constant over time.Keywords
This publication has 27 references indexed in Scilit:
- Lifestyle factors and symptoms of gastro‐oesophageal reflux – a population‐based studyAlimentary Pharmacology & Therapeutics, 2005
- Review article: alternative approaches to the long-term management of GERDAlimentary Pharmacology & Therapeutics, 2005
- Daily treatment with esomeprazole is superior to that taken on‐demand for maintenance of healed erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2005
- Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical prInternational Journal Of Clinical Practice, 2005
- PPI use in the OTC era: Who to treat, with what, and for how long?Clinical Gastroenterology and Hepatology, 2005
- Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease?Alimentary Pharmacology & Therapeutics, 2004
- Lifestyle related risk factors in the aetiology of gastro-oesophageal refluxGut, 2004
- Review article: treatment for gastro‐oesophageal reflux disease – lifestyle advice and medicationAlimentary Pharmacology & Therapeutics, 2004
- Six‐month trial of on‐demand rabeprazole 10 mg maintains symptom relief in patients with non‐erosive reflux diseaseAlimentary Pharmacology & Therapeutics, 2004
- Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiativeAlimentary Pharmacology & Therapeutics, 2003